Selective D1/D5 Receptor Agonism in Parkinson Disease: Insights from the TEMPO-3 Phase 3 Trial of Tavapadon

MedXY Editorial Team•Mar 28, 2026•Clinical Updates

Tavapadon, a first-in-class selective D1/D5 partial agonist, met its primary endpoint in the Phase 3 TEMPO-3 trial, significantly increasing ‘good-on-time’ in Parkinson’s disease (PD) patients.
The trial demonstrated a statistically significant increase of 1.10 hours in daily good-on-time compared to placebo (P < .001) over 26 weeks.
Key secondary outcomes showed a reduction in daily ‘off-time’ by 0.94 hours more than placebo, addressing a critical unmet need in patients with levodopa-induced motor fluctuations.
Tavapadon exhibited a favorable safety profile, with most adverse events categorized as mild to moderate, potentially avoiding some of the neuropsychiatric complications associated with traditional D2/D3-preferential agonists.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Tavapadon, a first-in-class selective D1/D5 partial agonist, met its primary endpoint in the Phase 3 TEMPO-3 trial, significantly increasing ‘good-on-time’ in Parkinson’s disease (PD) patients.
The trial demonstrated a statistically significant increase of 1.10 hours in daily good-on-time compared to placebo (P < .001) over 26 weeks.
Key secondary outcomes showed a reduction in daily ‘off-time’ by 0.94 hours more than placebo, addressing a critical unmet need in patients with levodopa-induced motor fluctuations.
Tavapadon exhibited a favorable safety profile, with most adverse events categorized as mild to moderate, potentially avoiding some of the neuropsychiatric complications associated with traditional D2/D3-preferential agonists.